HNGE Overview

Hinge Health, Inc. leverages software, including artificial intelligence (AI), to largely automate care for joint and muscle health. The Company has designed its TrueMotion platform to address a spectrum of musculoskeletal (MSK) care from acute injury to chronic pain, to post-surgical rehabilitation. Members receive personalized and automated MSK care through its AI-powered motion tracking technology. It offers electrical nerve stimulation wearable device Enso, all designed and monitored by its AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Its platform offers a range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. Enso delivers electrical nerve stimulation designed to provide non-addictive and non-invasive pain relief.

Wall Street analysts forecast HNGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HNGE is64.50 USD with a low forecast of 59.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Hinge Health Inc revenue for the last quarter amounts to 170.73M USD, increased 45.60

Hinge Health Inc. EPS for the last quarter amounts to 0.40 USD, increased 14.29

Hinge Health Inc (HNGE) has 1437 emplpoyees as of March 25 2026.

Today HNGE has the market capitalization of 3.22B USD.